Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: A 20-week Randomised, Double-blind, Placebo-controlled, Six Armed Parallel Group, Multi-centre, Multinational Trial With an Open Label Orlistat Comparator Arm and With an 84-week Extension Period
Latest Information Update: 03 Aug 2021
At a glance
- Drugs Liraglutide (Primary) ; Orlistat
- Indications Glucose intolerance; Obesity
- Focus Adverse reactions; Biomarker
- Sponsors Novo Nordisk
- 01 Nov 2016 Results of population pharmacokinetic analysis in obese patients of this and other two trials published in the Clinical Pharmacokinetics
- 04 Apr 2016 Results (pooled analysis of this and other four trials, n = 5338) assessing neuropsychiatric Safety Profile presented at The 98th Annual Meeting of the Endocrine Society.
- 07 Feb 2013 New trial record